Curis (CRIS) Upgraded at Zacks Investment Research

Curis (NASDAQ:CRIS) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a report released on Thursday.

According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. “

Separately, Guggenheim assumed coverage on shares of Curis in a research report on Monday, October 23rd. They issued a “buy” rating and a $7.00 price objective for the company. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Curis currently has an average rating of “Hold” and a consensus price target of $6.50.

Curis (CRIS) traded down $0.03 on Thursday, hitting $0.52. 2,049,372 shares of the company were exchanged, compared to its average volume of 1,535,174. The company has a debt-to-equity ratio of 1.24, a quick ratio of 5.15 and a current ratio of 5.15. Curis has a 1-year low of $0.48 and a 1-year high of $3.22. The company has a market cap of $85.04, a PE ratio of -1.30 and a beta of 1.56.

In other news, CEO Ali Ph.D. Fattaey bought 50,000 shares of the stock in a transaction on Wednesday, November 15th. The stock was purchased at an average price of $1.06 per share, for a total transaction of $53,000.00. Following the acquisition, the chief executive officer now owns 115,890 shares in the company, valued at $122,843.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 4.07% of the stock is currently owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the business. OxFORD Asset Management LLP bought a new position in Curis during the 2nd quarter worth about $115,000. FNY Partners Fund LP increased its holdings in Curis by 350.0% during the 3rd quarter. FNY Partners Fund LP now owns 67,500 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 52,500 shares in the last quarter. Voya Investment Management LLC increased its holdings in Curis by 21.8% during the 2nd quarter. Voya Investment Management LLC now owns 68,138 shares of the biotechnology company’s stock worth $129,000 after purchasing an additional 12,207 shares in the last quarter. Alliancebernstein L.P. increased its holdings in Curis by 338.7% during the 2nd quarter. Alliancebernstein L.P. now owns 83,800 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 64,700 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in Curis by 8.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 100,023 shares of the biotechnology company’s stock worth $190,000 after purchasing an additional 8,102 shares in the last quarter. Hedge funds and other institutional investors own 55.34% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Curis (CRIS) Upgraded at Zacks Investment Research” was posted by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/11/curis-cris-upgraded-at-zacks-investment-research.html.

Curis Company Profile

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Get a free copy of the Zacks research report on Curis (CRIS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply